92096-37-2

Usage

Uses

Used in Pharmaceutical Industry:
DIPHENYLMETHYL (7R)-3-(MESYLOXY)-7-(PHENYLACETAMIDO)-3,4-DIDEHYDROCEPHAM-4-CARBOXYLATE is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
DIPHENYLMETHYL (7R)-3-(MESYLOXY)-7-(PHENYLACETAMIDO)-3,4-DIDEHYDROCEPHAM-4-CARBOXYLATE is used as a key intermediate in organic synthesis for the preparation of complex organic molecules. Its versatile structure allows for further functionalization and modification, enabling the synthesis of a wide range of organic compounds with diverse applications.
Used in Ceftibuten Impurity:
DIPHENYLMETHYL (7R)-3-(MESYLOXY)-7-(PHENYLACETAMIDO)-3,4-DIDEHYDROCEPHAM-4-CARBOXYLATE is also used as an impurity in the synthesis of Ceftibuten, a third-generation cephalosporin antibiotic. Its presence in the synthesis process can affect the purity and quality of the final product, making it an important consideration in the development and manufacturing of Ceftibuten.

Upstream product

• 54639-48-4 (6R,7R)-benzhydryl 3-hydroxy-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 94796-13-1 diphenylmethyl 7β-phenylacetamido-3-vinyl-3-cephem-4-carboxylate 
• 29126-12-3 diphenylmethyl (6R-trans)-3-methyl-8-oxo-7-(phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 179035-99-5 benzhydryl 7β-(2-phenylacetamido)-3-(thiophen-2-yl)thio-3-cephem-4-carboxylate 
• 179035-29-1 benzhydryl 7β-(2-phenylacetamido)-3-(2-pyridyl)thio-3-cephem-4-carboxylate 
• 179035-25-7 benzhydryl 7β-(2-phenylacetamido)-3-(thiazol-2-yl)thio-3-cephem-4-carboxylate 
• 400827-68-1 4-(2-{[(6R,7R)-2-[(diphenylmethoxy)carbonyl]-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]sulfanyl}-1,3-thiazol-4-yl)pyridine 
• 194929-94-7 (6R,7R)-3-(4-Carboxymethyl-thiazol-2-ylsulfanyl)-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 194928-70-6 (6R,7R)-3-(4-Carbamoylmethyl-thiazol-2-ylsulfanyl)-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 140157-60-4 (6R,7R)-7-[2-[(Z)-1-Benzhydryloxycarbonyl-vinyloxyimino]-2-(2-tert-butoxycarbonylamino-thiazol-4-yl)-acetylamino]-8-oxo-3-(1-trityl-1H-[1,2,3]triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 

Relevant academic research and scientific papers

MANUFACTURING METHOD OF INTERMEDIATE FOR PREPARATION OF CEPHALOSPORIN DERIVATIVE AND CEFTAROLINE FOSAMIL METAL SALT MANUFACTURED THEREBY

The present invention relates to a method for preparing an intermediate for the preparation of a cephalosporin compound, and a ceftaroline fosamil metal salt obtained therefrom. According to the method for preparing an intermediate for the preparation of

CEPHALOSPORIN INTERMEDIATE AND PROCESS FOR ITS PREPARATION

Provided is a synthesis of cephalosporin derivatives, characterized by the use of the new intermediates for the preparation of cephalosporin derivatives, a crystalline toluene hemi-solvate of benzhydryl (6R,7R)-7β-[(phenylacetyl)amino]-3-[4-pyridyl-2-thia

studies on anti-helicobacter pylori agents. Part 2: New cephem derivatives

The synthesis and optimization of the anti-Helicobacter pylori activity of a novel series of cephem derivatives are described. Introduction of thio-heterocyclic groups containing N- and S-atoms to the 3-position and phenyl or thienyl acetamido groups to the 7-position of the cephem nucleus dramatically improved the activity. From this series of derivatives, compound 13i was found to have extremely potent in vitro anti-H. pylori activity, superior therapeutic efficacy compared to AMPC and CAM, no cross-resistance between CAM or MNZ and low potential for causing diarrhea due to instability to β-lactamase. Copyright (C) 2000 Elsevier Science Ltd.

Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative

The synthesis and anti-Helicobacter pylori activity of a novel cephem derivative FR182024 (1) are described. FR182024 having a (5-methyl-1,3,4-thiadiazol-2-yl)-thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have extremely potent in vitro anti-H.pylori activity, superior therapeutic efficacy to AMPC and CAM, and low potential for causing diarrhea.